Fig. 1: Patient disposition.
From: Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
The study opened for enrollment in November 2020; the first patient received their initial treatment on 22 April 2021, and the last patient was enrolled on 2 March 2023. Percentages reported are based on the number of patients randomized (intent-to-treat set). aOther (noncompliance/protocol violation (n = 2 in each arm) or withdrawal of consent (n = 11 in the pelabresib–ruxolitinib arm, and n = 4 in the placebo–ruxolitinib arm)). bTreatment ongoing as of 31 August 2023.
